For the quarter ending 2025-09-30, JAZZ had $136,190K increase in cash & cash equivalents over the period. $459,441K in free cash flow.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net income (loss) | 251,412 | -811,011 |
| Acquired in-process research and development | 42,500 | 905,362 |
| Intangible asset amortization | 168,368 | 316,551 |
| Share-based compensation | 88,125 | 132,154 |
| Acquisition accounting inventory fair value step-up adjustment | 40,355 | 66,989 |
| Depreciation | 9,878 | 22,331 |
| Non-cash interest expense | 5,299 | 21,914 |
| Provision for losses on accounts receivable and inventory | 8,223 | 6,771 |
| Deferred tax benefit | -271,410 | -110,252 |
| Other non-cash transactions | -1,016 | -7,042 |
| Accounts receivable | 50,996 | -10,530 |
| Inventories | 31,909 | 61,852 |
| Prepaid expenses and other current assets | 6,674 | -8,212 |
| Operating lease assets | -3,178 | -12,440 |
| Other non-current assets | -18,824 | 802 |
| Accounts payable | 62,358 | 6,465 |
| Accrued liabilities | 126,277 | -75,351 |
| Income taxes payable | 12,738 | 59,270 |
| Operating lease liabilities, less current portion | -3,475 | -2,887 |
| Other non-current liabilities | 529 | 4,763 |
| Net cash provided by operating activities | 474,616 | 518,639 |
| Acquisition of investments | 640,125 | 680,050 |
| Asset acquisition, net of cash acquired | 0 | 858,053 |
| Acquisition of intangible assets | 30,000 | 25,000 |
| Acquired in-process research and development | 42,500 | 0 |
| Purchases of property, plant and equipment | 15,175 | 26,848 |
| Proceeds from maturity of investments | 400,000 | 780,000 |
| Net cash used in investing activities | -327,800 | -809,951 |
| Repayments of long-term debt | 7,750 | 765,500 |
| Share repurchases | 0 | 125,023 |
| Payment of employee withholding taxes related to share-based awards | 3,812 | 69,412 |
| Proceeds from employee equity incentive and purchase plans | 733 | 21,944 |
| Repayment of 2024 notes | 0 | - |
| Net proceeds from issuance of 2030 notes | 0 | - |
| Net cash provided by (used in) financing activities | -10,829 | -937,991 |
| Effect of exchange rates on cash and cash equivalents | 203 | 6,319 |
| Net increase (decrease) in cash and cash equivalents | 136,190 | -1,222,984 |
| Cash and cash equivalents at beginning of period | 2,412,864 | - |
| Cash and cash equivalents at end of period | 1,326,070 | - |
Jazz Pharmaceuticals plc (JAZZ)
Jazz Pharmaceuticals plc (JAZZ)